Table 3.
Baseline patient characteristics according to quartiles of apoA2
| Characteristic | Quartile of ApoA2 at Baseline | P Value | |||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||
| Participants (n) | 232 | 314 | 338 | 367 | |
| Range (mg/dl) | 12–23 | 24–26 | 28–30 | 31–54 | |
| Age (yr) | 66.3 (7.8) | 66.7 (8.4) | 66.4 (8.0) | 65.9 (8.6) | 0.58 |
| Men (%) | 133 (57) | 176 (56) | 172 (51) | 193 (53) | 0.37 |
| Ever smoking, n (%) | 98 (42) | 131 (42) | 135 (40) | 140 (38) | 0.72 |
| Body mass index (kg/m2) | 27.4 (4.7) | 27.7 (4.8) | 27.6 (5.0) | 27.4 (4.6) | 0.74 |
| BP (mmHg) | |||||
| Systolic | 144 (23) | 147 (22) | 145 (21) | 146 (22) | 0.51 |
| Diastolic | 75 (11) | 75 (11) | 77 (11) | 76 (11) | 0.17 |
| Time receiving dialysis (mo) | 8.4 (7.1) | 8.3 (6.5) | 8.7 (7.6) | 7.8 (6.4) | 0.47 |
| History of disease, n (%)a | |||||
| Arrhythmia | 64 (28) | 66 (21) | 48 (14) | 57 (16) | <0.001 |
| MI, CABG, PCI, or CHD | 80 (34) | 99 (31) | 90 (27) | 100 (27) | 0.13 |
| Congestive heart failureb | 113 (49) | 125 (40) | 102 (30) | 102 (28) | <0.001 |
| Stroke or TIA | 42 (18) | 62 (20) | 53 (16) | 67 (18) | 0.59 |
| Peripheral vascular disease | 121 (52) | 151 (48) | 146 (43) | 141 (38) | 0.01 |
| Hemoglobin (g/dl) | 10.6 (1.4) | 10.9 (1.4) | 11.0 (1.3) | 11.1 (1.3) | <0.001 |
| Glycated hemoglobin (%) | 6.8 (1.2) | 6.8 (1.3) | 6.7 (1.2) | 6.7 (1.2) | 0.77 |
| Phosphate (mg/dl) | 6.00 (1.83) | 6.00 (1.57) | 6.09 (1.51) | 6.02 (1.60) | 0.86 |
| Albumin (g/dl) | 3.73 (0.31) | 3.81 (0.30) | 3.83 (0.29) | 3.86 (0.30) | <0.001 |
| Cholesterol (mg/dl) | |||||
| LDL | 117 (29) | 126 (27) | 126 (29) | 130 (32) | <0.001 |
| HDL | 28 (9) | 32 (10) | 37 (12) | 44 (15) | <0.001 |
| Apolipoprotein (mg/dl) | |||||
| A1 | 105.8 (13.6) | 115.9 (15.6) | 127.9 (16.9) | 146.8 (23.4) | <0.001 |
| A2 | 20.8 (2.1) | 25.2 (1.0) | 28.7 (1.0) | 35.2 (4.1) | <0.001 |
| C3 | 17.6 (10.2) | 19.8 (9.3) | 20.8 (9.1) | 22.4 (9.1) | <0.001 |
| Triglycerides (mg/dl) | 291 (209) | 271 (162) | 264 (157) | 241 (147) | 0.004 |
| C-reactive protein (mg/L) | 11.1 (5.8–18.9) | 8.4 (3.5–12.9) | 5.1 (2.1–11.1) | 4.4 (1.9–11.1) | <0.001 |
| NT-pro-BNP (ng/L) | 5713 (2558–13,735) | 3415 (1402–8652) | 2510 (1118–6649) | 2742 (1310–6473) | <0.001 |
Data are presented as the mean (SD) or median (25th percentile to 75th percentile), unless otherwise specified. P values for comparison of groups were derived from an analysis of covariance model (for continuous variables) or logistic regression model (for categorical variables), both adjusted for age and sex. Q, quartile; MI, myocardial infarction; CABG, coronary artery bypass grafting surgery; PCI, percutaneous coronary intervention; CHD, coronary heart disease, documented by coronary angiography; TIA, transitory ischemic attack; NT-pro-BNP, N-terminal pro-brain natriuretic peptide.
Types of disease and intervention are not mutually exclusive.
Predominantly New York Heart Association II.